FDA warns on rare side effect of breast cancer meds

|About: Pfizer Inc. (PFE)|By:, SA News Editor

The FDA has issued a warning concerning the incidence of rare severe lung inflammation in some patients receiving Pfizer's (PFE -0.8%) Ibrance (palbociclib), Novartis' (NVS -2%) Kisqali (ribociclib) or Eli Lilly's (LLY -0.3%) Verzenio (abemaciclib), all cyclin-dependent kinase 4/6 inhibitors.

Labeling has been updated about the risk. The agency recommends that patients talk to their doctors before considering stopping treatment.

Subscribe for full text news in your inbox